Publications
Export 91 results:
Filters: Author is Roy, Marc-André [Clear All Filters]
“Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study.”, Br J Psychiatry, pp. 1-8, 2022.
“Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study.”, Acta Psychiatr Scand, vol. 145, no. 5, pp. 456-468, 2022.
, “For a structured response to the psychosocial consequences of the restrictive measures imposed by the global COVID-19 health pandemic: the MAVIPAN longitudinal prospective cohort study protocol.”, BMJ Open, vol. 12, no. 4, p. e048749, 2022.
“Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations.”, Clin Psychopharmacol Neurosci, vol. 20, no. 1, pp. 194-198, 2022.
“What areas of everyday functioning are affected by theory of mind deficits in recent-onset schizophrenia spectrum disorders?”, Early Interv Psychiatry, 2022.
Sante Ment Que, vol. 46, no. 2, pp. 19-21, 2021.
, “A Chart Audit Study of Clozapine Utilization in Early Psychosis.”, J Clin Psychopharmacol, vol. 41, no. 3, pp. 275-280, 2021.
, “Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.”, J Psychopharmacol, vol. 35, no. 9, pp. 1152-1157, 2021.
“[Detecting and Treating Comorbid Disorders in First-Episode Psychosis: A Lever for Recovery].”, Sante Ment Que, vol. 46, no. 2, pp. 307-330, 2021.
“[Early Intervention for Psychosis from Past to Future: Overcoming Implementation Challenges to Maximize its Impact?]”, Sante Ment Que, vol. 46, no. 2, pp. 391-415, 2021.
“[Family Approaches in Early Intervention: Benchmarks to Guide Intervention and Support Families in First Episode Psychosis Programs (FEPP)].”, Sante Ment Que, vol. 46, no. 2, pp. 139-159, 2021.
“[From Kraepelin to McGorry: Scientific Vision and Experiential Narrative around a Major Paradigmatic Shift].”, Sante Ment Que, vol. 46, no. 2, pp. 23-43, 2021.
“[A Healthy Mind in a Healthy Body: The Value of Physical Activity for Youth With First Episode Psychosis].”, Sante Ment Que, vol. 46, no. 2, pp. 249-276, 2021.
, “Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program.”, CNS Drugs, vol. 35, no. 4, pp. 461-468, 2021.
“[Psychopharmacology of First Episode Psychosis: An Approach Based on Recovery].”, Sante Ment Que, vol. 46, no. 2, pp. 113-137, 2021.
, “Urbanicity, Schizophrenia and Equitable Specialist Services Allocation.”, Can J Psychiatry, p. 7067437211040606, 2021.
, “Circulating IGFBP-2 levels reveal atherogenic metabolic risk in schizophrenic patients using atypical antipsychotics.”, World J Biol Psychiatry, pp. 1-8, 2020.
, “The Evolution of Long-Acting Antipsychotics Use in Québec between 2003 and 2017.”, Can J Psychiatry, vol. 65, no. 7, pp. 510-511, 2020.
, “From QAAPAPLE 1 to QAAPAPLE 2: How do we move from one algorithm to another one with Long acting antipsychotics (LAIs).”, Expert Rev Neurother, 2020.
, “A multimodal attempt to follow-up linkage regions using RNA expression, SNPs and CpG methylation in schizophrenia and bipolar disorder kindreds.”, Eur J Hum Genet, vol. 28, no. 4, pp. 499-507, 2020.
, “Personalized cognitive remediation therapy to facilitate return to work or to school in recent-onset psychosis.”, Neurocase, vol. 26, no. 6, pp. 340-352, 2020.
, “Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports.”, J Clin Psychopharmacol, vol. 40, no. 2, pp. 191-194, 2020.
, “"Real world" clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients.”, Psychopharmacology (Berl), 2020.
, “Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence.”, J Clin Psychopharmacol, vol. 39, no. 4, pp. 393-397, 2019.
